New York, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, ...
– Additional Posters Underscore Broad Potential of J-Brain Cargo ® Platform, Including Preclinical Data for Pabinafusp Alfa in MPS II and Nonclinical Data for JR-446 in MPS IIIB – "The data presented ...
PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has ...
Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks ...
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II >80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain ...
A Prescription Drug User Fee Act target date of January 5, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...
Purpose: To evaluate the safety and efficacy of recombinant human iduronate-2-sulfatase (idursulfase) in the treatment of mucopolysaccharidosis II. Methods: Ninety-six mucopolysaccharidosis II ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured ...
Recent successful meeting with the FDA provides path to file for accelerated approval and subsequent conversion to full approval Plan to submit biologics license application (BLA) early in 2025 under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback